Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	10/531,895	GEISSER ET AL.
	Examiner	Art Unit
	JOHN PAK	1616
All Participants:	Status of Applica	tion:
(1) <u>Examiner Pak</u> .	(3) <u>Mr. Corff</u> .	
(2) <u>Mr. Clark</u> .	(4)	1
Date of Interview: 28 September 2007	Time:	
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Exhibit Shown or Demonstrated: ☐ Yes ☐ N If Yes, provide a brief description: On 9/19/200	No 7, Examiner Pak faxed to Mr.	
amendment of the claims for discussion. A copy of	of this fax is attached hereto f	or the record.
Part I.		
Rejection(s) discussed:		
Claims discussed:		
See the attached fax.		
Prior art documents discussed:		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE See Continuation Sheet	E GENERAL NATURE OF W	HAT WAS DISCUSSED:
Part III.		
 It is not necessary for applicant to provide a sed directly resulted in the allowance of the application of the interview in the Notice of Allowability. It is not necessary for applicant to provide a sed did not result in resolution of all issues. A brief 	ition. The examiner will provide parate record of the substan	de a written summary of the substance ce of the interview, since the interview
	•	
Olh		
(Examiner/SPE Signature) (A	Applicant/Applicant's Represe	ntative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed:

Mr. Clark stated on 9/19/2007 that Mr. Corff would get back to the Examiner next week. Mr. Corff contacted the Examiner on 9/24/2007 and inquired about taking out the pH condition and the time condition in step (B). The Examiner agreed to consider such a change but stated that further review was necessary (further review was always necessary, as indicated by the coversheet to the fax). Mr. Corff indicated that he would present the changed amendments to applicant for discussion. On 9/25/2007, Mr. Corff stated that applicant would like an Office action on the claims as currently pending. No agreement was thus reached.



Patent Technology Centers

Facsimile Transmission

To:

Name:

Mr. Clark / Mr. Corff

Company:

Fax Number:

912165669711

Voice Phone:

From:

Name:

Examiner John Pak

Official Fax Number:

(571) 273-8300 (571) 273-8300

Official After Final Fax Number:

571-272-0620

Voice Phone:

37 C.F.R. 1.6 sets forth the types of correspondence that can be communicated to the Patent and Trademark Office via facsimile transmissions. Applicants are advised to use the certificate of facsimile transmission procedures when submitting a reply to a non-final or final Office action by facsimile (37 CFR 1.8(a)).

Fax Notes:

Please review these changes and let me know if you can authorize these changes, conditioned on their allowability. Upon receiving your conditional authorization, I can complete the examination work to ensure allowability. An answer by Monday, September 24, would be appreciated.

John Pak Primary Examiner 571-272-0620

Date and time of transmission: Wednesday, September 19, 2007 10:59:58 AM

Number of pages including this cover sheet: 02

Claim Amendments for Discussion

Claim 1. (Currently amended) A water soluble iron carbohydrate complex

- (A) providing one or more maltodextrins, where, when one maltodextrin is provided, its dextrose equivalent is between 5 and 20, and when a mixture of several maltodextrins is provided, the dextrose equivalent of the mixture is between 5 and 20 and the dextrose equivalent of each individual maltodextrin contained in the mixture is between 2 and 40;
- (B) oxidizing said one or more maltodextrins in an aqueous hypochlorite solution, which aqueous hypochlorite solution is at pH 8 to 12 and has a concentration of at least 13% by weight active chlorine, for 10 minutes to 4 hours, to provide oxidized maltodextrins; and
- (C) reacting the oxidized maltodextrins with iron (III) salt in an aqueous solution to provide a water soluble iron carbohydrate complex;

wherein

- (i) the iron (III) salt amount is selected to provide 10 to 40% by weight iron content in the complex, and
- (ii) the weight average molecular weight of the complex is 80 kDa to 400 kDa,
- Amend all other claims to correspond to above. Same language carried throughout.
- Rewrite "Use of' claims to acceptable U.S. method claims.
- Rephrase "prophylaxis" as reducing the incidence of iron deficiency.
- Other minor language changes are expected in order to conform to above.
- Insert 371 data at the top of the specification, below the Title.